Canada · Delayed Price · Currency is CAD VVT Med Statistics
Total Valuation
VVT Med has a market cap or net worth of CAD 21.78 million. The enterprise value is 23.20 million.
| Market Cap | 21.78M |
| Enterprise Value | 23.20M |
Important Dates
The next estimated earnings date is Tuesday, September 1, 2026.
| Earnings Date | Sep 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VVT Med has 72.59 million shares outstanding. The number of shares has increased by 76.91% in one year.
| Current Share Class | 72.59M |
| Shares Outstanding | 72.59M |
| Shares Change (YoY) | +76.91% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 7.02% |
| Owned by Institutions (%) | 0.00% |
| Float | 67.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 202.62 |
| PB Ratio | -6.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 215.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.14
| Current Ratio | 0.14 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.37 |
| Interest Coverage | -8.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -195.76% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 132.17% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 13,435 |
| Profits Per Employee | -699,675 |
| Employee Count | 8 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 58.46 |
| Average Volume (20 Days) | 11,607 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, VVT Med had revenue of CAD 107,481 and -5.60 million in losses. Loss per share was -0.10.
| Revenue | 107,481 |
| Gross Profit | 73,981 |
| Operating Income | -3.85M |
| Pretax Income | -5.60M |
| Net Income | -5.60M |
| EBITDA | -3.85M |
| EBIT | -3.85M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 92,127 in cash and 1.51 million in debt, with a net cash position of -1.42 million or -0.02 per share.
| Cash & Cash Equivalents | 92,127 |
| Total Debt | 1.51M |
| Net Cash | -1.42M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -3.26M |
| Book Value Per Share | -0.05 |
| Working Capital | -3.51M |
Cash Flow
In the last 12 months, operating cash flow was -4.04 million and capital expenditures -6,979, giving a free cash flow of -4.05 million.
| Operating Cash Flow | -4.04M |
| Capital Expenditures | -6,979 |
| Depreciation & Amortization | 4,252 |
| Net Borrowing | 654,862 |
| Free Cash Flow | -4.05M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | 68.83% |
| Operating Margin | -3,585.72% |
| Pretax Margin | -5,207.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VVT Med does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -76.91% |
| Shareholder Yield | -76.91% |
| Earnings Yield | -25.70% |
| FCF Yield | -18.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 31, 2025. It was a reverse split with a ratio of 0.2141328.
| Last Split Date | Jul 31, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2141328 |
Scores
VVT Med has an Altman Z-Score of -53.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -53.07 |
| Piotroski F-Score | 3 |